A perilous prescription: The dangers of unregulated drug ads

During the COVID-19 pandemic, as many stayed home, direct-to-consumer prescription drug advertising—already big business—boomed. Websites, social media, streaming services, and other on-demand platforms became ideal real estate for drug manufacturers, start up clinics, telemedicine practitioners, and others to market drugs, whether they were FDA-approved or not.

Read More

Pick a Card, Any Card: Undergrad Startup Combines Flashcards with Augmented Reality for Neurodivergent Students

In traditional classrooms, young students might spend the day sitting still for extended periods while listening to teachers talk, sometimes too fast. It’s not a system that works for all, often leaving behind those who learn differently, such as neurodivergent students with conditions like dyslexia, attention-deficit/hyperactivity disorder (ADHD), or autism. Justin Nappi ’24 (CLAS) and…

Read More

The top 10 drugs losing US exclusivity in 2023

[Excerpt] Takeda is defending its key brands on multiple fronts this year, but it’s the loss of exclusivity on Vyvanse—the Japanese pharma’s third best-selling product—that’s going to hurt the most. First approved back in 2007 to treat attention-deficit/hyperactivity disorder (ADHD), Vyvanse—known generically as lisdexamfetamine dimesylate—will likely face its first copycat competitors after the drug’s last…

Read More

Music Therapy Helps Ease Depression in Children, Adolescents With ADHD

A study found that music therapy has positive applications as an alternative treatment for depression in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). In the study, the authors determined that participants experienced positive psychological and neurophysiological effects because the music therapy activated serotonin (5-HT) and improved participants’ ability to cope with stress.1

Read More